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ABSTRACT

It is the object of the current invention to provide methods and

compositions relating to the expression ofvankyrin proteins
in cell lines to increase their viability, longevity and capacity
for protein production. The inventors have discovered that the
expressionofP-ank:-1 and f -ank:-3 proteins in cell culture has
increased the cells' longevity and capacity for endogenous
and/or heterologous target protein production. Specifically,
the present invention relates to the enhanced expression of
endogenous and/or heterologous target proteins/polypeptides
in recombinant cells that are also expressing P-ank:-1 and/or
I2 -ank-3 protein compared to expression host cells that are not
expressing P-ank:-1 and/or f-ank:-3 protein.
24 Claims, 6 Drawing Sheets
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P-ankyrin-1: eDNA (SEQ ID NO: 1)
ATGGAGATTTCTCAAATTCGAAAGCTATTCGGTAAAAACCGCGTCACGAAAAATACCATATTTC
ACGAGCTTGCCCACGCTGGATCATTGACACTACTGTACCGGGTTCGAGACAACATTGACGAGCC
ATGCAGCTCTATCCTGCAAGAGGTTAATGCTGATGGAGACTATAGTATCCATGTG~CGGCAAAG

ACGCACCGAGGACAGCTTGCAGTGAGGATCATACAGGTGCTACTAGAGTTAGGGGCAAACCTGA
ATGCGAAAGATCGTGTCTGGAACTTTACTGTACTGCATGTCGCAGTTGAGCGAGACGATTACGT
CCTCGCAAAGTGGCTGCGCCATCACCCACAAATTGATTTGGATGCAAGAGGTTGGGATGGACTT
ACGGCACATGAAACGTCGTTGATAACGTGCAACAAAGAGATGATGGATATTTTCCGAACCGACG
GTGTTAACAGAGCCGGTGGTACAGAGCCGAAAGTGAATGAAAGTACATCGAATGACAATCAGCA
T

P-ankyrin-1: Protein (SEQ ID NO: 2)
MEISQIRKLFGKNRVTKNTIFHELAHAGSLTLLYRVRDNIDEPCSSILQEVNADGDYSIHVAAK
THRGQLAVRIIQVLLELGANLNAKDRVWNFTVLHVAVERDDYVLAKWLRHHPQIDLDARGWDGL.
TAHETSLITCNKEMMDIFRTDGVNRAGGTEPKVNESTSNDNQH

12-ankyrin-3: eDNA (SEQ ID NO: 3)
ATGGAAAATTCTCAAATTGCAAAGCTGTTCGGTACAAACTGGGTCACGAAAAATACCATATTTC
ACGAGCTTGCCCACGCTGGATCGTTGACACTTCTTCACCGGGTTCGACACAACATTCAAGAGCC
ATGCAGCTCTATCCTGCAAGAGGTTAATGCTAATGGAGACTATAGTATTCATGTGGCGGCAAAA
ACGCACCGAGGACAGCTCGCAGTGAGGATCATTCAGATACTACTGGAATTGGGGGCTAATCTGA
ATGCAAGAGATCGTGTCTGGAACTTTACTGTACTGCATGTCGCAGTTGAGCGGGAGGATTACGT
CCTCACAATGTGGCTGCGCCATCACCCACAAATGGATTTGAATGCGAGAGGTTTCGCTGGACTT
ACGGCACATCAAATGGCGTTGATGTCGTGCGACAGAAAGATGATGGATATTTTCCGAACCGACG
CTGTATACGGAGCCGGTGGTTCAGAGCCGAAAGTGAATGAAAGTACATCGAATGACAATCAGCA
T
2

1 -ankyrin-3: Protein (SEQ ID NO: 4)
MENSQIAKLFGTNWVTKNTIFHELAHAGSLTLLHRVRHNIQEPCSSILQEVNANGDYSIHVAAK
THRGQLAVRIIQILLELGANLNARDRVWNFTVLHVAVEREDYVLTMWLRHHPQMDLNARGFAGL
TAHQMALMSCDRKMMDIFRTDAVYGAGGSEPKVNESTSNDNQH

Figure 3
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Approximate Yields of Vankyrin Proteins off of Nickei-NTA Columns
(QIAGEN)
P-ank-1
P-ank-2
P-ank~3

P-ank-4
12-ank-1
12-ank-2
12-ank-3

Average Concentration of Eluted Proteins {from 25ml
Culture)
1.22 mg/ml (In 2.05mL)
0.9035 mg/mL (in 1.50ml)
1.009 mg/ml (in 1.360ml)
0.9904 mg/ml (in 1.500ml)
0.9382 mg/mL (in 1.500ml)
1.002 mg/ml (in 1.500ml)
1.18 mg/mL (in 2.050ml)

I

~

~

=
~

Aggroximate Yield
{1 L Culture)
100.04 mg/L
54.21 mg/L
54.89 mg/L
59.42 mg/L
56.29 mg/L
60.12 mg/l
96.76 mg/L
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Approximate purity of eluted proteins: 60-75%
Proteins were collected 1 day prior to apparent cell lysis in infected Sf9 Cells
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Yield Calculation: 1.22mg/ml X 2.05 mL = 2.501 mg
2.501 mg/ .025L Culture = 100.04 mg/L
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VECTORS AND METHODS FOR ENHANCED
CELL LONGEVITY AND PROTEIN
EXPRESSION

(1983). Several advantages may exist when employing the
BEY system. One of these advantages is the strong polyhedrin promoter which directs a high level of expression of the
inserted heterologous nucleic acid encoding the target
polypeptide. The newly expressed heterologous target protein accumulates in large amounts within these infected insect
cells. Thus, as a result of the relative strength of the polyhedrin promoter, many different gene inserts can be expressed at
very high levels.
In addition to providing a high expression level, another
advantage of the BEY system is the ease with which these
baculoviruses are produced and identified. This process
begins by co-transfecting wild -type viral DNA and a "transfer
vector" into susceptible host cells. A transfer vector is defined
as a bacterial plasmid which contains a desired gene directly
3' to the polyhedrin promoter, as well as long viral sequences
flanking the promoter on the 5' side. During cotransfection,
homologous recombination occuring between viral and
transfer vector DNA will produce a small percentage of viral
genomes in which the polyhedrin gene has been replaced by
the desired heterologous nucleic acid encoding the target
polypeptide (0.1-5.0% ). The wild-type progeny can be differentiated from the recombinant progeny by a conventional
viral plaque assay. Recombinants in which the polyhedrin
gene has been replaced, can be identified by their occlusionnegative plaque phenotype observed in a background of
occlusion-positive wild-type plaques.
Because the polyhedrin gene is a non-essential gene for
productive viral infection, another advantage ofbaculovirus
expression vectors is that the recombinants are viable, helperindependent viruses. Also, baculoviruses only infect Lepidopteran insects; thus, they are noninfectious for vertebrates,
and are, therefore, relatively safe genetic manipulation
agents.
Notwithstanding the successes of BEYS and other systems
for expression of heterologous proteins in insect and mammalian cell culture, maintenance of the viability of transformed or transfected cell cultures remains a capricious
undertaking. Many laboratories refer to tissue culture as a
"black art," due to the numerous variables that make it difficult to determine solutions when problems arise. An intensive
and time-consuming systematic approach that examines the
symptoms and meticulously retraces each step in the culture
process is usually required to identify the material or critical
procedure that has created the viability issue. Problems such
as poor cell growth and abnormal morphology can result from
materials that are poor quality, inappropriate, compromised,
or contaminated and/or equipment that must be re-calibrated
or re-setup to comply with manufacturer usage. Perhaps most
frustrating, cells of different lots may react differently to
standardized media and serum supplements resulting in unexpected toxicity or nutritional deficiency. Therefore, much of
the time and expense invested in preparation of protein
expression vectors may be lost when a protein production
facility experiences difficulty in optimizing cell culture protein production conditions. As such it would be of great
economic benefit to provide a generalized agent to a cell line
to increase its viability, longevity and protein production
capacity.
Insects, like other animals, have effective immune systems
to combat both biotic and abiotic foreign invasion. Interestingly, endoparasitic insects spend a part of their life cycle
inside the body of other insect hosts. Considerable effort has
been expended investigating the mechanism by which these
endoparasitic insects avoid the host immune system in this
parasitic relationship.

BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to the fields of nucleic acid constructs and cell lines that allow for the increased expression of
endogenous or heterologous target protein.
2. Background
The immediate challenge created by the genomics era is
the production of the novel proteins to understand their function. Current methods of expressing genes in a marmnalian
cell include the use of viral vectors, such as those which are
derived from retroviruses, adenoviruses, herpes viruses, vaccinia viruses, polio viruses, sindbis viruses, or adena-associated viruses. Other methods of expressing an exogenous gene
in a mammalian cell include direct injection of DNA, the use
of ligand-DNA conjugates, the use of adenovirus-ligandDNA conjugates, calcium phosphate precipitation, and methods which utilize a liposome- or polycation-DNA complex.
Due to its advantages in versatility and speed, the Baculovirus Expression Vector System (BEYS) used in conjunction with insect cells has become well-established for the
production of proteins, particularly recombinant glycoproteins. Baculovirus mediated protein expression provides correct folding of recombinant protein as well as disulfide bond
formation, oligomerization and other important post-translational modifications that impart proper biological activity and
function. With regard to protein folding and post-translational
processing, insect cells are second only to marmnalian cell
lines when expressing a eukaryotic protein, for example. The
frequent use of baculovirus arises from the relative ease and
speed with which a heterologous protein can be expressed on
the laboratory scale and the high chance of obtaining a biologically active protein. Insect cells can be grown on serum
free media which is an advantage in terms of costs as well as
of biosafety. For large scale culture, conditions have been
developed which meet the special requirements of insect
cells.
In nature, baculoviruses are double-stranded DNA-containing viruses that infect a variety of different insect species.
The nuclear polyhedra sis viruses, which comprise subgroup
A of the Family Baculoviridae, induce the formation of
paracrystalline occlusion bodies in the nuclei of infected host
cells. These occlusion bodies are composed primarily of a
single viral protein which is expressed at very high levels
(polyhedrin). In later stages of the infection cycle, polyhedrin
may account for more than 50% of the total protein in an
infected cell. The polyhedrin gene has been cloned and
sequenced and its unique features have provided the basis for
the development of a series ofbaculovirus expression vectors
(BEYs: Summers, M.D. and Smith, G. E., TAES Bull. 1555
(1987); Luckow, V. A. and Summers, M.D., Biotechnology
6:47-55 (1988); Miller, L. K., Ann. Rev. Microbial. 42:177179 (1988); U.S. Pat. No. 4,745,051, G. E. Smith and M.D.
Summers (Filed May 27, 1983; Issued May 17, 1988)).
BEYs are recombinant baculoviruses in which the coding
sequence for polyhedrin has been replaced with the coding
sequence for a desired protein. In general, this approach
involves the construction and isolation of recombinant baculoviruses in which the coding sequence for the chosen gene
has been inserted behind the promoter for the nonessential
polyhedrin viral gene (Pennica, eta!, Mol. Cell. Bioi. 4:399406 (1984); Smith, eta!, L. Viral. 46:584-593 (1983); Smith,
G. E. and M. D. Summers, Mol. Cell. Bioi. 3:2156-2165
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One well characterized parasitoid-host system in which
there is immune system evasion is that of the endoparasitic
wasp Campoletis sonorensis and its host, the tobacco budworm Heliothis virescens. In investigating how immunosuppression is regulated in this system, it became apparent that a
group of wasp viruses, known generically as polydnaviruses
(PDVs), play a role in the suppression of the host immune
system. Bracoviruses (BVs) and ichnoviruses (IVs) are the
two main parasitic wasp associated PDVs. It is known that
during oviposition, the endoparasitic insect, for example C.
sonorensis, injects not only eggs but also polydnavirus and
oviduct proteins. Shortly thereafter, the host insect immune
system begins to show evidence of altered activity and the
endoparasitoid eggs remain free from encapsulation. The precise mechanism of this immune suppression is not presently
understood.
The WHv1.0, WHv1.6 and VHv1.1 genes of C. sonorensis
polydnavirus (CsPDV) have been cloned and sequenced.
These genes are described as members of a polydnavirus
"cysteine-rich" gene family. (Dib-Hajj et a!., Proc. Nat!.
Acad. Sci. (USA) 90: 3765 (1993)). It has been conjectured
that these genes may play a role in preventing the recognition
of foreign objects and/or the normal response of components
of the immune system. (S=ers eta!., Proc. Natl.Acad. Sci.
(USA) 92: 29 (1995)). Indeed, the VHv 1.1 gene product of
the C. sonorensis polydnavirus has been implicated in the
inhibition of the cellular immune response. This 30 kDa protein is shown by indirect immunofluorescence to bind both
granulocytes and plasmatocytes and is thought to inhibit
encapsulation. (Li eta!., J. Viral., 68: 7482 (1994)).
Recent PDV genome sequencing projects have revealed a
novel family of closely related genes that exist in several
genomes including, but not limited to, the C. sonorensis IV
(CsiV) Hyposoter fugitivus IV (HfiV), Glyptafumiferana IV
(GfiV), Microplitis demolitor BV (MdBV), Cotesia congregata BV (CcBV), Glyptapanteles indiensis BV (GiBV), and
Toxoneuron nigriceps BV (TnBV) genomes. This family of
genes has been named vankyrins as their open reading frames
(ORFs) encode proteins almost exclusively made up of
ankyrin repeat domains. The PDV ankyrin repeat-carrying
proteins show significant identity to the ankyrin repeats of the
IK~ family of transcription factor inhibitors suggesting that
they disrupt intracellular NF -K~ mediated signal transduction
cascades known to play a role in both vertebrate and invertebrate immune responses. There are seven vankyrin ORFs
encoded by the CsiV genome.
The inventors have discovered that the expression of two
CsiV vankyrins from a heterologous expression vector system increases the vitality, longevity, and therefore the protein
productive capacity of cells in culture.
All references cited herein are hereby incorporated by reference in their entirety for all purposes.

acid of SEQ ID NO: 3 under stringent conditions wherein the
nucleic acid encodes a polypeptide capable of enhancing
longevity and/or protein production of a cell line in which it is
expressed. Another aspect of the invention relates to a
vankyrin expression vector comprising a nucleic acid of SEQ
ID NO: 1. Yet another aspect relates to a vankyrin expression
vector comprising a nucleic acid of SEQ ID NO: 3.
Another aspect of the invention relates to a recombinant
cell comprising a first nucleic acid selected from the group
consisting of a nucleic acid encoding the polypeptide of SEQ
ID NO: 2 a nucleic acid that hybridizes to the nucleic acid of
SEQ ID NO: 1 under stringent conditions wherein the nucleic
acid encodes a polypeptide capable of enhancing longevity
and/or protein production of a cell line in which it is
expressed; and a nucleic acid of SEQ ID NO: 1; and/or a
second nucleic acid selected from the group consisting of: a
nucleic acid encoding the polypeptide of SEQ ID NO: 4; a
nucleic acid that hybridizes to the nucleic acid of SEQ ID NO:
3 under stringent conditions wherein the nucleic acid encodes
a polypeptide capable of enhancing longevity and/or protein
production of a cell line in which it is expressed; and a nucleic
acid of SEQ ID NO: 3.
Another aspect of the invention relates to a method of
enhancing target protein production of a cell line producing a
target protein comprising transforming cells of the cell line
with a vankyrin expression vector, growing the cell line; and
isolating the target protein from the cell line.
Another aspect of the invention relates to a method of
generating a recombinant cell line capable of enhanced target
protein production comprising transforming a cell line with a
heterologous nucleic acid encoding and driving the expression of a target protein; and transforming cells of the cell line
with a vankyrin expression.
Yet another aspect of the invention relates to a method of
generating a recombinant target protein-producing cell line
capable of enhanced target protein production comprising
constructing a vankyrin expression vector and transforming
cells of the cell line with the vankyrin expression vector.
Another aspect of the invention relates to a method of
enhancing longevity of a cell line producing a target protein
comprising transforming cells of the cell line with a vankyrin
expression vector, to obtain a transformed cell line producing
a target protein; growing the transformed cell line producing
a target protein longer than a the cell line not transformed with
the vector.
Additional advantages of the present invention will
become readily apparent to those skilled in this art from the
following detailed description, wherein only the preferred
embodiment of the invention is shown and described, simply
by way of illustration of the best mode contemplated of carrying out the invention. As will be realized, the invention is
capable of other and different embodiments, and its several
details are capable of modifications in various obvious
respects, all without departing from the invention. The
present invention may be practiced without some or all of
these specific details. In other instances, well known process
operations have not been described in detail, in order not to
unnecessarily obscure the present invention. Accordingly, the
drawings and description are to be regarded as illustrative in
nature, and not as restrictive.
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One aspect of the invention relates to a vankyrin expression
vector comprising a nucleic acid encoding the polypeptide of
SEQ ID NO: 2. Another aspect of the invention relates to a
vankyrin expression vector comprising a nucleic acid encoding the polypeptide of SEQ ID NO: 4. Yet another aspect of
the invention relates to a vankyrin expression vector comprising a nucleic acid that hybridizes to the nucleic acid of SEQ
ID NO: 1 under stringent conditions wherein the nucleic acid
encodes a polypeptide capable of enhancing longevity and/or
protein production of a cell line in which it is expressed. A
further aspect of the invention relates to a vankyrin expression
vector comprising a nucleic acid that hybridizes to the nucleic

60
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FIG. 1. Morphology of 4-day post infected (4 d p.i.) Sf9
(panel A) and S1-2 (panel B) cells exposed to recombinant
AcMNPV's expressing CsiV vankyrin proteins. Cells
infected with recombinant viruses expressing fat body spe-
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6

cific P-ank:-1 and f -ank:-3 proteins (asterisks) are more stable
and resemble non-infected cells at 4 d p.i. Cells exposed to
recombinant viruses expressing the remaining CsiV genes
undergo apoptosis and lysis by 4 d p.i. and resemble cells
infected with wild type AcMNPV. 40x magnification.
FIG. 2. Protein expression is extended in Sf9 cells infected
with recombinant AcMNPV expressing Fat-Body specific
CsiV ankyrin genes P-ank:-1 and I 2 -ank:-3. Western blots represent detection of proteins in freshly overlayed culture media
presented to cells at each subsequent day following infection.
The CsiV vankyrin genes are intracellular proteins and lack
secretory signals, thus protein detected in the media overlay is
the result of that released by cell lysis or rupture following
infection. Delayed detection of proteins from P-ank:-1 and
I 2 -ank-3 viruses until day 3 p.i. is resultant of the enhanced
longevity of Sf9 cells occurring early during infection by
these viruses (as evidenced in FIG. 1).
FIG. 3. The eDNA and amino acid sequences of P-ank:-1
(SEQ ID NO: 1 and 3, respectively) and I2 -ank-3 (SEQ ID
NO: 2 and 4, respectively).
FIG. 4. Morphology of Sf9 cells exposed to recombinant
AcMNPV's expressing CsiV vankyrin proteins over time.
Cells infected with recombinant viruses expressing fat body
specific P-ank:-1 and I 2 -ank-3 proteins (asterisks) are more
stable and increase the longevity of the cells through 6 days ( 6
D) post infection such that they resemble non-transfected
control cells. Cells exposed to recombinant viruses expressing the remaining CsiV genes undergo apoptosis and lysis by
4 d p.i. and resemble cells infected with wild type AcMNPV.
40x magnification.
FIG. 5. Morphology ofS1-2 cells exposed to recombinant
AcMNPV's expressing CsiV vankyrin proteins over time.
Cells infected with recombinant viruses expressing fat body
specific P-ank:-1 and I 2 -ank-3 proteins (asterisks) are more
stable and maintain the vitality of the cells through 6 days ( 6
D) post infection such that they resemble non-transfected
control cells. Cells exposed to recombinant viruses expressing the remaining CsiV genes undergo apoptosis and lysis by
4 d p.i. and resemble cells infected with wild type AcMNPV.
40x magnification.
FIG. 6. Shows the yield of recombinant vankyrin protein
produced in cells infected by different recombinant AcMNPVs. A cell line was infected with different recombinant
AcMNPVs encoding different vankyrin proteins. Next, the
vankyrin protein encoded by the each differing recombinant
AcMNPV was isolated and quantified. The inventors note
that cells infected by recombinant AcMNPVs encoding
P-ank:-1 and I 2 -ank:-3 produced significantly larger quantities
of their encoded CsiV vankyrin proteins, i.e., P-ank:-1 and
I 2 -ank:-3 protein, respectively, than cells transgenically
expressing the other CsiV vankyrin proteins.

The seven vankyrin genes are f -ank:-1, I 2 -ank:-2, I 2 -ank:-3,
P-ank:-1, P-ank:-2, P-ank:-3 and P-ank:-4. The inventors have
discovered that the expression of P-ank:-1 and I 2 -ank:-3 proteins in cell culture has increased the cells' viability, longevity
and, therefore, capacity for endogenous and/or heterologous
target protein production. Specifically, the present invention
relates to the enhanced expression of endogenous and/or heterologous target proteins/polypeptides in recombinant cells
that are also expressing P-ank-1 and/ orl 2 -ank-3 protein compared to expression host cells that are not expressing P-ank:-1
and/or f-ank:-3 protein.
Before describing the invention in greater detail the following definitions are set forth to illustrate and define the
meaning and scope of the terms used to describe the invention
herein:
The term "nucleic acid molecule" is meant to include
DNA, RNA and mixed DNA-RNA sequences. In addition to
the typically found A, T, U, G and C residues, a nucleic acid
molecule may also include related residues such as, for
example, inosine (I).
The term "polynucleotide" or "oligonucleotide" as used
herein refers to a polymeric form of nucleotides of any length,
either ribonucleotides or deoxyribonucleotides. This term
refers only to the primary structure of the molecule. Thus, this
term includes double and single stranded DNA, triplex DNA,
as well as double and single stranded RNA. It also includes
modified, for example, by methylation and/ or by capping, and
unmodified forms of the polynucleotide.
The term "promoter region" refers to a DNA sequence that
functions to control the transcription of one or more nucleic
acid sequences, located upstream with respect to the direction
of transcription of the transcription initiation site of the gene,
and is structurally identified by the presence of a binding site
for DNA-dependent RNA polymerase, transcription initiation sites and any other DNA sequences, including, but not
limited to transcription factor binding sites, repressor and
activator protein binding sites, calcium or cAMP responsive
sites, and any other nucleotide sequences known to act
directly or indirectly to regulate transcription from the promater.
The term "heterologous DNA" or "heterologous RNA"
refers to DNA or RNA that does not occur naturally as part of
the genome or DNA or RNA sequence in which it is present,
or in which it is found, a cell or location or locations in the
genome or DNA or RNA sequence that differs from that
which it is in found in nature. Heterologous DNA or RNA is
not endogenous to the cell into which it is introduced, but has
been obtained from another cell or synthetically or recombinantly produced. Generally, though not necessarily, such
DNA encodes RNA and protein not normally produced by the
cell in which the DNA is transcribed or expressed. Similarly
exogenous RNA encodes protein not normally expressed in
the cell in which the exogenous RNA is present. Heterologous
DNA or RNA may also be referred to as foreign DNA or
RNA. Any DNA or RNA that one of skill in the art would
recognize as heterologous or foreign to the cell in which it is
expressed is herein encompassed by the term heterologous
DNA or heterologous RNA. Examples ofheterologous DNA
include, but are not limited to, DNA that encodes a protein,
polypeptide, reporter nucleic acid sequence, transcriptional
or translational regulatory sequences, selectable or traceable
marker protein, such as a protein that confers drug resistance,
RNA including mRNA and antisense RNA, and ribozymes.
The term "recombinant polynucleotide" as used herein
refers to a polynucleotide of genomic, eDNA, semisynthetic
or synthetic origin which, by virtue of its origin or manipulation: (1) is not associated with all or a portion of the poly-
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DETAILED DESCRIPTION OF THE INVENTION
It is an object of the current invention to provide methods
and compositions relating to the expression ofvankyrin proteins in cell lines to increase their viability, longevity and
capacity for protein production. The vankyrin gene family
comprises 7 genes on CsiV genome segments P and I2 . Each
vankyrin gene encodes an open reading frame of about 500bp possessing 4 ankyrin repeat protein motifs. The vankyrin
protein motifs show significant identities to ankyrin motifs of
Cactus, the Drosophila IKB protein. MdBV and CsiV
vankyrin genes align with the 4 C-terminal ankyrin repeat
domains ofiKBs but lack N-terminal repeats that function to
mask nuclear localization signals (NLS) and sequester uninduced NF -KB dimers in the cytoplasm.
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nucleotide with which it is associated in nature and/or (2) is
linked to a polynucleotide other than that to which it is linked
in nature. The term "eDNA" or "complementary DNA" refers
to single stranded or double stranded DNA sequences
obtained by reverse transcription of messenger RNA isolated
from a donor cell. For example, treatment of messenger RNA
with a reverse transcriptase such as AMV reverse transcriptase or M-MuLV reverse transcriptase in the presence of
an oligonucleotide primer will furnish an RNA-DNA duplex
which can be treated with RNase H, DNA polymerase and
DNA ligase to generate double stranded eDNA. If desired, the
double stranded eDNA can be denatured by conventional
techniques such as shearing to generate single stranded
eDNA.
The term "operably linked" refers to the linkage of a DNA
segment to another DNA segment in such a way as to allow
the segments to function in their intended manners. A DNA
sequence encoding a gene product is operably linked to a
regulatory sequence when it is ligated to the regulatory
sequence, such as, for example, promoters, enhancers and/or
silencers, in a manner which allows modulation of transcription of the DNA sequence, directly or indirectly. For example,
a DNA sequence is operably linked to a promoter when it is
ligated to the promoter downstream with respect to the transcription initiation site of the promoter, in the correct reading
frame with respect to the transcription initiation site, and
allows transcription elongation to proceed through the DNA
sequence. An enhancer or silencer is operably linked to a
DNA sequence coding for a gene product when it is ligated to
the DNA sequence in such a manner as to increase or
decrease, respectively, the transcription of the DNA
sequence. Enhancers and silencers may be located upstream,
downstream or embedded within the coding regions of the
DNA sequence. A DNA for a signal sequence is operably
linked to DNA coding for a polypeptide if the signal sequence
is expressed as a preprotein that participates in the secretion
of the polypeptide. Linkage of DNA sequences to regulatory
sequences is typically accomplished by ligation at suitable
restriction sites or via adapters or linkers inserted in the
sequence using restriction endonucleases known to one of
skill in the art.
The term "target" protein or polypeptide, refers to a protein
of interest that is expressed in the recombinant cells also
expressing P-ank-1 and/or f-ank-3 protein. Preferably, the
recombinant cell is used as bioreactor for the production of
the target protein. The target protein may be an endogenous
protein naturally produced by the host cell type. For example,
if the host cell type is a hybridoma, the target protein may be
a monoclonal antibody. Alternatively, the target protein can
be encoded by a heterologous recombinant nucleic acid, e.g.
a eDNA. In this case, the target protein will be a heterologous
protein, i.e., one that is not naturally expressed by the host cell
line.
Central to the invention is the "vankyrin expression vector." A vankyrin expression vector is any genetic element,
e.g., a plasmid, chromosome, virus, capable ofbringing about
the expression of a P-ank-1 (SEQ ID NO: 2) and/or f -ank-3
(SEQ NO: 4) proteins or proteins substantially similar
thereto, i.e., those having similar amino acid sequences and
the same functionalities with regard to the ability to provide
enhanced cell longevity and/or protein productive capacity.
Preferably, proteins P-ank-1 (SEQ ID NO: 2) and I2 -ank-3
(SEQ NO: 4) are encoded by SEQ ID NO: 1 and SEQ NO: 3,
respectively. The skilled artisan will also appreciate that
invention also encompasses vankyrin expression vector
sequences comprising sequences substantially identical to

SEQ ID NOs: 1 and 3. Such sequences may differ from SEQ
ID NOs: 1 and 3, respectively, with regard to the identity of at
least one nucleotide base.
However, all polynucleotides sequences "substantially
identical" to SEQ ID NOs: 1 and 3 hybridize under stringent
conditions (as defined herein) to all or a portion of the
complements of SEQ ID NOs: 1 and3 (i.e., target sequences),
respectively. The terms "hybridize(s) specifically" or "specifically hybridize(s)" refer to complementary hybridization
between an oligonucleotide (e.g., a primer or labeled probe)
and a target sequence. The term specifically embraces minor
mismatches that can be accommodated by reducing the stringency of the hybridization media to achieve the desired priming for the PCR polymerases or detection of hybridization
signal.
Under stringent hybridization conditions, only highly
complementary, i.e., substantially identical nucleic acid
sequences, hybridize. Preferably, such conditions prevent
hybridization of nucleic acids having 3 or more mismatches
out of 20 contiguous nucleotides, more preferably 2 or more
mismatches out of 20 contiguous nucleotides, most preferably one or more mismatch out of 20 contiguous nucleotides.
The hybridizing portion of the hybridizing nucleic acid is at
least about 90%, preferably at least about 95%, or most preferably about at least about 98%, identical to the sequence of
a target sequence, or its complement.
Hybridization of a nucleic acid to a nucleic acid sample
under stringent conditions is defined below. Nucleic acid
duplex or hybrid stability is expressed as a melting temperature (T m), which is the temperature at which the probe dissociates from the target DNA. This melting temperature is used
to define the required stringency conditions. If sequences are
to be identified that are substantially identical to the probe,
rather than identical, then it is useful to first establish the
lowest temperature at which only homologous hybridization
occurs with a particular concentration of salt (e.g. SSC or
SSPE). Then assuming that 1% mismatching results in a 1o C.
decrease in T m' the temperature of the final wash in the
hybridization reaction is reduced accordingly (for example, if
sequences having >95% identity with the probe are sought,
the final wash temperature is decrease by 5° C.). In practice,
the change in T m can be between 0.5° C. and 1.5° C. per 1%
mismatch.
Stringent conditions involve hybridizing at 68° C. in
5xSSC/5xDenhardt's solution/1.0% SDS, and washing in
0.2xSSC/0.1% SDS at room temperature. Moderately stringent conditions include washing in 3xSSC at 42° C. Additional guidance regarding such conditions is readily available
in the art, for example, Sambrook, Fischer and Maniatis,
Molecular Cloning, a laboratory manual, (2nd ed.), Cold
Spring Harbor Laboratory Press, New York, (1989) and F. M.
Ausubel et a! eds., Current Protocols in Molecular Biology,
John Wiley and Sons (1994).
Moreover, vankyrin expression vector containing polynucleotides "substantially similar or identical" to SEQ ID
NO: 1 and 3, respectively, are capable of providing a cell line
with enhanced longevity and/or protein production capability. In one embodiment, when expressed in Sf9 or S1-2 cells,
polynucleotides "substantially similar or identical" to SEQ
ID NO: 1 and 3, respectively, are capable of improving the
longevity of those cells to such an extent that they resemble
non-transfected Sf9 or S1-2 cells, whereas Sf9 or S1-2 cells
transfected with a vector not containing polynucleotides
"substantially similar or identical" to SEQ ID NO: 1 and 3,
respectively. Preferably, the vector is a baculovirus vector. In
another embodiment, polynucleotides "substantially similar
or identical" to SEQ ID NO: 1 and 3, respectively, are capable
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of providing enhanced protein production in a cell line in
which they are expressed, relative to a host cell line transfected in a similar manner by a vector lacking such polynucleotides. For example, polynucleotides "substantially similar or
identical" to SEQ ID NO: 1 and 3, respectively, when
expressed in Sf9 or S1-2 cells, are capable providing
enhanced protein production in those cells, relative to Sf9 or
S 1-2 cells transfected with a vector not containing polynucleotides "substantially similar or identical" to SEQ ID NO: 1
and 3, respectively.
The vankyrin expression vector contains sequences to
facilitate expression of P-ank-1 and/or I2 -ank-3 proteins in
the host cell. Such sequences differ depending on the host
organism; they include promoter sequences, for example but
not limited to a polyhedrin promoter, SV40 promoter, or a
conditionally activated promoter such as a metallothionein
promoter to effect transcription; enhancer sequences to
increase transcription; ribosomal binding site sequences; and
transcription and translation termination sequences. The vector may also optionally behave either as an autonomous unit
of polynucleotide replication within a cell (i.e., capable of
replication nnder its own control) or being rendered capable
of replication by insertion into a host cell chromosome, having attached to it another polynucleotide segment, so as to
bring about the replication. Suitable vectors include, but are
not limited to, viruses, plasmids, bacteriophages, yeast artificial chromosomes (YACs ), cosmids, and the like. Vectors
may contain polynucleotide sequences which are necessary
to effect ligation or insertion of the vector into a desired host
cell and the expression of its coding region(s ). Additionally,
the vankyrin expression vector itself may also contain heterologous nucleic acids encoding and driving the expression of
target heterologous proteins and/or reporter proteins.
The skilled artisan will recognize that a wide range of
vectors may be constructed to permanently, constitutively,
conditionally or transiently drive P-ank-1 and/or f-ank-3
expression in a wide range of insect and mammalian cell
lines. The skilled artisan would know how to operably link the
aforementioned sequences. It is to be understood that this
invention is intended to include other forms of expression
vectors, host cells and transformation techniques which serve
equivalent functions and which become known to the art
hereto.
The preferred "vankyrin expression vector" is part of a
baculovirus expression system engineered to express P-ank-1
and/or I 2 -ank-3 proteins nnd the control of a polyhedrin promoter in the cells it infects. Most, preferably, the baculovirus
is an Autographa californica baculovirus (AcNPV), and
expression of P-ank-1 and/or I2 -ank-3 protein is driven by a
polyhedrin promoter. The baculovirus Autographa californica mono nuclear polyhedrosis virus (AcMNPV), used in
the examples as the original source of viral DNA was isolated
according to procedures described in G. E. Smith and M.D.
Summers, Virology, 89:517-527 (1978) and G. E. Smith and
M.D. Summers, J. Viral., 39:125-137 (1981). According to
the preferred embodiment of this invention, a particular strain
of AcMNPV, E2, is utilized. However, those skilled in the art
who have the benefit of this disclosure will recognize that
other baculoviruses and other baculovirus strains may also be
suitably utilized to obtain viral DNA. In particular, it is
expected that at least the closely related and naturally occurring strains, Trichoplusia ni MNP\1, Rachiplusia au MNP\1,
Galleria mellonella MNPV and any plaque-purified strains
such as the M3' R9, S1 and S3 strains of AcMNPV isolated
and characterized in G. E. Smith and M. D. Summers, J.
Viral., 33:311-319 (1980), as well as Bombyx mori NPV
(BmNPV) may be utilized to advantage. Further description

of those and other strains are fonnd in G. E. Smith and M.D.
Summers, Viral., 89:517-527 (1978).
Plasmids for the aforementioned BEYS carrying SEQ ID
NO: 1 and/or 3, or sequences substantially similar thereto,
may be designed according to conventional techniques
known in the art and as described in M.D. Summers and G. E.
Smith, A Manual of Methods for Baculovirus Vectors and
Insect Cell Culture Procedures, Texas Agricultural Experiment Station Bulletin No. 1555, Texas A&M University
(1987) ("Bulletin No. 1555"). (See also V. A. Luckow and M.
D. Summers, Viral., 170:31-39 (1989)). In the preferred
embodiment, the Baculovirus Expression Vector System
from BD Biosciences Pharmingen is used which employs a
modified Autographa californica nuclear polyhedrosis virus
(AcNPV) genome-BD BaculoGold™ DNA, and an appropriate transfer vector. The diversity of AcNPV-based transfer
vectors, combined with available S. frugiperda Sf9 and Sf21
cell lines, establish baculovirus expression as a preferred
system for functional eukaryotic gene expression and the
large-scale production of recombinant proteins.
Although the methodology described herein is believed to
contain sufficient detail to enable one skilled in the art to
practice the present invention, the plasmids can be constructed and purified using standard recombinant DNA techniques described in T. Maniatis, E. F. Fritsch and J. Sambrook, Molecular Cloning: A Laboratory Manual, Cold
Spring Harbor Laboratory (1982) under the current regulations described in United States Dept. of HEW, National
Institute of Health (NIH) Guidelines for Recombinant DNA
Research. These references include procedures for the following standard methods: cloning procedures with E. coli
plasmids, transformation of E. coli cells, plasmid DNA purification, phenol extraction of DNA, ethanol precipitation of
DNA, agarose gel electrophoresis, purification of DNA fragments from agarose gels, and restriction endonuclease and
other DNA-modifYing enzyme reactions. Accordingly, these
available references are incorporated herein by reference.
A "reporter nucleic acid sequence" is a DNA molecule that
expresses a detectable gene product, which may be reporter
RNA or reporter protein. The detection may be accomplished
by any method known to one of skill in the art. For example,
detection of mRNA expression may be accomplished by
using Northern blot analysis and detection of protein may be
accomplished by staining with antibodies specific to the protein, e.g. Western blot analysis. Preferred reporter nucleic
acid sequences are those that are readily detectable. A
reporter nucleic acid sequence may be operably linked in a
DNA construct with a regulatory DNA sequence such that
detection of the reporter nucleic acid sequence product provides a measure of the transcriptional activity of the regulatory sequence. Examples of reporter nucleic acid sequences
include, but are not limited to, those coding for alkaline
phosphatase, chloramphenicol acetyl transferase (CAT),
luciferase, beta-galactosidase and alkaline phosphatase.
The terms "transformed" or "transfected" are used interchangeably and refer to the process by which exogenous
DNA or RNA is transferred or introduced into an appropriate
host cell. Additionally, nucleic acids encoding other heterologous proteins may be introduced into the host cell. Such
transfected cells include stably transfected cells wherein the
inserted DNA is rendered capable of replication in the host
cell. Typically, stable transfection requires that the exogenous
DNA be transferred along with a selectable marker nucleic
acid sequence, such as for example, a nucleic acid sequence
that confers antibiotic resistance, which enables the selection
of the stable transfectants. This marker nucleic acid sequence
may be ligated to the exogenous DNA or be provided inde-
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pendently by simultaneous cotransfection along with the
exogenous DNA. Transfected cells also include transiently
expressing cells that are capable of expressing the RNA or
DNA for limited periods of time. The transfection procedure
depends on the host cell being transfected. It can include
packaging the polynucleotide in a virus as well as direct
uptake of the polynucleotide. Transformation can result in
incorporation of the inserted DNA into the genome of the host
cell or the maintenance of the inserted DNA within the host
cell in plasmid form. Methods oftransformation/transfection
are well known in the art and include, but are not limited to,
direct injection, such as microinjection, viral infection, particularly replication-deficient adenovirus infection, electroporation, lipofection, calcium phosphate-mediated direct
uptake and the like.
The term "host cell" generally refers to eukaryotic cells
and includes any transformable cell which is capable of
expressing a P-ank-1 and/or I 2 -ank-3 proteins and can be, or
has been, used as a recipient for a vankyrin expression vector.
Once cells have transiently or stably taken up the vankyrin
expression vector they are "recombinant" cells. DNA is commonly transferred or introduced into recipient mammal cells
by calcium phosphate-mediated gene transfer, electroporation, lipofection, viral infection and the like. General methods, vectors and general considerations for gene transfer and
expression may be found in M. Kriegler, Gene Transfer and
Expression: A Laboratory Manual, Stockton Press (1990).
Direct gene transfer to cells in vivo is achieved by the use of
modified viral vectors, including retroviruses, adenoviruses,
adena-associated viruses and herpes viruses, liposomes, and
direct injection of DNA into certain cell types. See, e.g.,
Wilson, Nature, 365: 691-692 (1993); Plautz et al,Annals NY
Acad. Sci., 716: 144-153 (1994); Farhood eta!, Annals NY
Acad. Sci., 716: 23-34 (1994) and Hyde eta! Nature, 362:
250-255 (1993).
Recombinant cells provided by this invention expressing
P-ank-1 and/or I2 -ank-3 proteins are intended to produce
target polypeptides, preferably human proteins and fragments thereof. The process involves culturing the recombinant cells under conditions wherein the endogenous or heterologous target proteins are expressed, e.g., by inducing the
activity of a conditional promoter, and purifYing the target
protein from the cell culture. Purification of target proteins is
within the skill set or the skilled artisan and generally involves
the steps of cell lysis, homogenization, centrifugation and
separation of the desired protein by processes such as salt
fractionation, precipitation, and a variety of chromatographic
methods such as anion exchange chromatography, hydrophobic interaction chromatography, high resolution chromatography, gel filtration chromatography and the like.
One aspect of this invention, relates to cells transiently
expressing a vankyrin expression vector. In one embodiment
of this aspect of the invention, the transient expression of the
P-ank-1 and/or I2 -ank-3 proteins serves to temporarily
strengthen the vitality of the culture expressing them. It is
envisaged that this temporary increase in vitality will allow
for the increased production of target proteins produced by
and harvested from the host cell line. For example, an established monoclonal antibody (Mab )-producing hybridoma
cell line may be transiently transfected with the vankyrin
expression element to obtain an increase in antibody production. The most simple method for in vitro production ofMabs
is standard tissue culture in either large flasks or roller bottles.
The production of Mab by hybridomas in tissue culture is
hybridoma-dependent and can vary between 1-100 flg/ml.
Therefore, it is often necessity to concentrate Mab from
supernatant. Transfecting a hybridoma with the vankyrin

expression element will allow for increased Mab production
and lessen the need for a technician to concentrate antibody in
the supernatant.
In another embodiment of this aspect of the invention, the
cells transiently transfected with a vankyrin expression vector
are also transiently or permanently co-transfected with an
additional expression element having a heterologous nucleic
acid sequence encoding and driving the expression of a heterologous target protein.
Another aspect of the invention relates to cells in which a
vankyrin expression element is stably integrated into the
cells' genome, thus rendering a recombinant cell line that
provides superior protein productive capacity when compared to its wild type cell counterpart. In one embodiment of
this aspect of the invention, such a cell line is amenable to
further permanent transfection with an additional expression
vector carrying a nucleic acid sequence encoding a target
protein of interest. In another embodiment, such a cell line is
amenable to transient transfection with an additional expression vector carrying a nucleic acid sequence encoding a target
protein of interest. In another embodiment, the target proteins
produced by and harvested from the cells having permanently
integrated vankyrin expression vectors may be proteins
endogenously produced by the host cells themselves.
Yet a further aspect of the invention relates to a vankyrin
expression vector that contains additional nucleic acid
sequences encoding one or more heterologous target proteins
of interest. Such a vector could be permanently or transiently
introduced into a host cell line.
The recombinant cells having the "vankyrin expression
vector" expressing P-ank-1 and/or f-ank-3 proteins are
mammalian, such as, but not limited to Chinese hamster
ovary (CHO) cells, COS-7 cells, fibroblasts as well as C127,
3T3, CHO, HeLa and BHK cell lines. Most preferably, the
cells are insect cells such as, but not limited to S2 cells,
Schneider cells, S12 cells, 5B1-4, Tn5, and Sf9 cells. The
Spodoptera frugiperda Sf9 cell line may be obtained from
American Type Culture Collection (Rockville, Md.) and is
assigned accession number ATCC CRL 1711. See M. D.
Summers and G. E. Smith, Bulletin No. 1555, suora. Those
skilled in the art who have the benefit of this disclosure will
recognize that other clonal derivatives of the Sf9 cell line as
well as Trichoplusia ni and other insects such as the silkworm,
Bombyx mori, or insect cell cultures derived there from can be
used to advantage.
The standard methods of insect cell culture, cotransfection
and preparation of plasmids in accordance with the examples,
are set forth in M.D. S=ers and G. E. Smith, A Manual of
Methods for Baculovirus Vectors and Insect Cell Culture
Procedures, Texas Agricultural Experiment Station Bulletin
No. 1555, TexasA&M University (1987). This reference also
pertains to the standard methods of cloning genes into AcMNPV transfer vectors, plasmid DNA isolation, transferring
genes into the AcMNPV genome, viral DNA purification,
radio labelling recombinant proteins and preparation of insect
cell culture media. Accordingly, this available reference is
incorporated herein by reference.
The procedures for the cultivation of viruses and cells are
described in L. E. Volkman and M.D. Summers, J. Viral,
19:820-832 (1975) andL. E. Volkman, M.D. Summers and C.
H. Hsieh, J. Viral, 19:820-832 (1976). Viral growth kinetics
were determined as described by L. E. Volkman, eta!., suora,
using S. frugiperda and a 1.5% agarose overlay.
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For example, when expressed in Sf9 or S1-2 cells, polynucleotides "substantially similar or identical" to SEQ ID
NO: 1 and 3, respectively, are capable improving the longevity of those cells to such an extent that they resemble non-
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transfected Sf9 or S 1-2 cells, whereas Sf9 or S 1-2 cells transfected with a vector not containing polynucleotides
"substantially similar or identical" to SEQ ID NO: 1 and 3,
respectively, rapidly lyse about 4 days post infection. FIG. 1.
Moreover, the longevity of a cell line expressing polynucleotides "substantially similar or identical" to SEQ ID NO: 1
and 3, respectively, continues to be maintained such that it
resembles non-infected cells at about 6 to about 7 days post
infection. FIGS. 2, 4 and 5. Therefore, when an Sf9 or S1-2
cell line is infected with a AcMNPV comprising polynucleotides "substantially similar or identical" to SEQ ID NO: 1 or
3, respectively, the infected Sf9 or S 1-2 cell line has enhanced
longevity relative to an Sf9 or S1-2 cell line infected with a
wild type AcMNPV.

tion in those cells, relative to Sf9 or S1-2 cells transfected
with a vector not containing polynucleotides "substantially
similar or identical" to SEQ ID NO: 1 and 3, respectively. As
can be seen in FIG. 2, protein expression is extended in Sf9
cells infected with recombinant AcMNPV expressing CsiV
ankyrin genes P-ank-1 and I2 -ank-3. Western blots in FIG. 2,
represent detection of proteins in freshly overlayed culture
media presented to cells at each subsequent day following
infection. The CsiV vankyrin genes are intracellular proteins
and lack secretory signals, thus protein detected in the media
overlay is the result of that released by cell lysis or rupture
following infection. Delayed detection of proteins from
P-ank-1 and I 2 -ank-3 viruses until day 3 post infection is
resultant of the enhanced longevity of Sf9 cells occurring
early during infection by these viruses (as evidenced in FIG.
1). Additionally, because cells expressing polynucleotides
"substantially similar or identical" to SEQ ID NO: 1 and 3,
respectively, are able to produce proteins for a longer period
of time, they are able to produce more protein in total, thus
providing an enhanced protein production capability. Therefore, when an Sf9 or S 1-2 cell line is infected with aAcMNPV
comprising polynucleotides "substantially similar or identical" to SEQ ID NO: 1 or 3, respectively, the infected Sf9 or
S 1-2 cell line has enhanced protein production relative to an
Sf9 or S 1-2 cell line infected with a wild type AcMNPV.

Example 2
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Polynucleotides "substantially similar or identical" to SEQ
ID NO: 1 and 3, respectively, are capable of providing
enhanced protein production in a cell line in which they are
expressed, relative to a host cell line transfected in a similar
manner by a vector lacking such polynucleotides. Specifically, polynucleotides "substantially similar or identical" to
SEQ ID NO: 1 and 3, respectively, when expressed in Sf9 or
S1-2 cells, are capable providing enhanced protein produc-

20

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS, 4
<210>
<211>
<212>
<213>

SEQ ID NO 1
LENGTH, 513
TYPE, DNA
ORGANISM, Campoletis sonorensis

<400> SEQUENCE, 1
atggagattt ctcaaattcg aaagctattc ggtaaaaacc gcgtcacgaa aaataccata

60

tttcacgagc ttgcccacgc tggatcattg acactactgt accgggttcg agacaacatt

120

gacgagccat gcagctctat cctgcaagag gttaatgctg atggagacta tagtatccat

180

gtggcggcaa agacgcaccg aggacagctt gcagtgagga tcatacaggt gctactagag

240

ttaggggcaa acctgaatgc gaaagatcgt gtctggaact ttactgtact gcatgtcgca

300

gttgagcgag acgattacgt cctcgcaaag tggctgcgcc atcacccaca aattgatttg

360

gatgcaagag gttgggatgg acttacggca catgaaacgt cgttgataac gtgcaacaaa

420

gagatgatgg atattttccg aaccgacggt gttaacagag ccggtggtac agagccgaaa

480

gtgaatgaaa gtacatcgaa tgacaatcag cat

513

<210>
<211>
<212 >
<213>

SEQ ID NO 2
LENGTH, 171
TYPE, PRT
ORGANISM: Campoletis sonorensis

<400> SEQUENCE, 2
Met Glu Ile Ser Gln Ile Arg Lys Leu Phe Gly Lys Asn Arg Val Thr
1
5
10
15
Lys Asn Thr Ile Phe His Glu Leu Ala His Ala Gly Ser Leu Thr Leu
20
25
30
Leu Tyr Arg Val Arg Asp Asn Ile Asp Glu Pro Cys Ser Ser Ile Leu
35
40
45
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16
-continued

Gln Glu Val Asn Ala Asp Gly Asp Tyr Ser Ile His Val Ala Ala Lys
50
55
60
Thr His Arg Gly Gln Leu Ala Val Arg Ile Ile Gln Val Leu Leu Glu
65
70
75
80
Leu Gly Ala Asn Leu Asn Ala Lys Asp Arg Val Trp Asn Phe Thr Val
85
90
95
Leu His Val Ala Val Glu Arg Asp Asp Tyr Val Leu Ala Lys Trp Leu
100
105
110
Arg His His Pro Gln Ile Asp Leu Asp Ala Arg Gly Trp Asp Gly Leu
115
120
125
Thr Ala His Glu Thr Ser Leu Ile Thr Cys Asn Lys Glu Met Met Asp
130
135
140
Ile Phe Arg Thr Asp Gly Val Asn Arg Ala Gly Gly Thr Glu Pro Lys
145
150
155
160
Val Asn Glu Ser Thr Ser Asn Asp Asn Gln His
165
170

<210>
<211>
<212>
<213>

SEQ ID NO 3
LENGTH, 513
TYPE, DNA
ORGANISM, Campo let is sonorensis

<400> SEQUENCE, 3
atggaaaatt ctcaaattgc aaagctgttc ggtacaaact gggtcacgaa aaataccata

60

tttcacgagc ttgcccacgc tggatcgttg acacttcttc accgggttcg acacaacatt

120

caagagccat gcagctctat cctgcaagag gttaatgcta atggagacta tagtattcat

180

gtggcggcaa aaacgcaccg aggacagctc gcagtgagga tcattcagat actactggaa

240

ttgggggcta atctgaatgc aagagatcgt gtctggaact ttactgtact gcatgtcgca

300

gttgagcggg aggattacgt cctcacaatg tggctgcgcc atcacccaca aatggatttg

360

aatgcgagag gtttcgctgg acttacggca catcaaatgg cgttgatgtc gtgcgacaga

420

aagatgatgg atattttccg aaccgacgct gtatacggag ccggtggttc agagccgaaa

480

gtgaatgaaa gtacatcgaa tgacaatcag cat

513

<210> SEQ ID NO 4
<211> LENGTH, 171
<212> TYPE, PRT
<213> ORGANISM: Campoletis sonorensis

<400> SEQUENCE, 4
Met Glu Asn Ser Gln Ile Ala Lys Leu Phe Gly Thr Asn Trp Val Thr
1
5
10
15
Lys Asn Thr Ile Phe His Glu Leu Ala His Ala Gly Ser Leu Thr Leu
20
25
30
Leu His Arg Val Arg His Asn Ile Gln Glu Pro Cys Ser Ser Ile Leu
35
40
45
Gln Glu Val Asn Ala Asn Gly Asp Tyr Ser Ile His Val Ala Ala Lys
50
55
60
Thr His Arg Gly Gln Leu Ala Val Arg Ile Ile Gln Ile Leu Leu Glu
65
70
75
80
Leu Gly Ala Asn Leu Asn Ala Arg Asp Arg Val Trp Asn Phe Thr Val
85
90
95
Leu His Val Ala Val Glu Arg Glu Asp Tyr Val Leu Thr Met Trp Leu
100
105
110
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18
-continued

Arg His His Pro Gln Met Asp Leu Asn Ala Arg Gly Phe Ala Gly Leu
115

120

125

Thr Ala His Gln Met Ala Leu Met Ser Cys Asp Arg Lys Met Met Asp
130

135

140

Ile Phe Arg Thr Asp Ala Val Tyr Gly Ala Gly Gly Ser Glu Pro Lys
145

150

155

160

Val Asn Glu Ser Thr Ser Asn Asp Asn Gln His
165

170

What is claimed is:
ii. a first nucleic acid sequence that hybridizes to the
15
nucleic acid of SEQ ID NO: 1 under stringent condi1. A vankyrin expression vector comprising the nucleic
tions comprising hybridizing at 68° in 5xSSC/5xDenacid sequence encoding the polypeptide of SEQ ID NO: 2 and
hardt's solution/1.0% SDS, and washing in 0.2xSSC/
a nucleic acid encoding the polypeptide of SEQ ID NO: 4.
0.1% SDS at room temperature and a second nucleic
2. A vankyrin expression vector comprising the nucleic
acid sequence that hybridizes to SEQ ID NO: 3 under
acid sequence encoding the polypeptide of SEQ ID NO: 4. 20
stringent conditions comprising hybridizing at 68° in
3. A vankyrin expression vector comprising a first nucleic
5xSSC/5xDenhardt's solution/1.0% SDS, and washacid that hybridizes to the full-length complement of the
ing in 0.2xSSC/0.1% SDS at room temperature;
nucleic acid of SEQ ID NO: 1 under stringent conditions
wherein the first and second nucleic acid sequences
comprising hybridizing at 68° C. in 5xSSC/5xDenhardt's
each encode a polypeptide capable of enhancing lonsolution/1.0% SDS, and washing in 0.2xSSC/0.1% SDS at 25
gevity and/or protein production of a cell line in which
room temperature; and a second nucleic acid that hybridizes
it is expressed, compared to wild type cell counterpart
to the full-length complement of SEQ ID NO: 3 under strinof the cell line;
gent conditions comprising hybridizing at 680 in 5xSSC/5x
iii. a nucleic acid comprising SEQ ID NO: 1 and SEQ ID
Denhardt's solution/1.0% SDS, and washing in 0.2xSSC/
N0:3;
0.1% SDS at room temperature; wherein the first and second 30
iv. a nucleic acid encoding the polypeptide of SEQ ID
nucleic acids each encode a polypeptide capable of enhancing
N0:4;
longevity of a cell line in which it is expressed and/or enhancv. a nucleic acid that hybridizes to the nucleic acid of
ing production of one or more target proteins optionally
SEQ ID NO: 3 under stringent conditions comprising
encoded by the vector compared to wild type cell counterpart
hybridizing at 680 in 5xSSC/5xDenhardt's solution/
of the cell line.
1.0% SDS, and washing in 0.2xSSC/0.1% SDS at
35
4. A vankyrin expression vector comprising a nucleic acid
room temperature; wherein the nucleic acid encodes a
polypeptide capable of enhancing longevity and/or
that hybridizes to the full-length complement of SEQ ID NO:
protein production of a cell line in which it is
3 under stringent conditions comprising hybridizing at 680 in
expressed, compared wild type cell counterpart of the
5xSSC/5xDenhardt's solution/1.0% SDS, and washing in
cell line; and
0.2xSSC/0.1% SDS at room temperature; wherein the 40
vi. the nucleic acid of SEQ ID NO: 3;
nucleic acid encodes a polypeptide capable of enhancing
b. growing said cell line; and
longevity of a cell line in which it is expressed and/or enhancc. isolating said target protein from said cell line.
ing production of one or more target proteins optionally
11. A method of generating a recombinant cell line capable
encoded by the vector compared to wild type cell counterpart
of the cell line.
45 of enhanced target protein production comprising:
a. transforming a cell line with a heterologous nucleic acid
5. A vankyrin expression vector comprising the nucleic
encoding and expressing one or more target proteins;
acid sequence of SEQ ID NO: 1 and the nucleic acid sequence
and
ofSEQIDN0:3.
b. transforming cells of said cell line with a vankyrin
6. A vankyrin expression vector comprising the nucleic
expression vector; said vankyrin expression vector comacid sequence of SEQ ID NO: 3.
50
prising a polynucleotide selected from the group con7. The vankyrin expression vector of any one of claims 1 to
sisting of:
6 wherein the vankyrin expression vector is a baculovirus
i.
a nucleic acid encoding the polypeptide of SEQ ID
vankyrin expression vector.
NO: 2 and the polypeptide of SEQ ID NO: 4;
8. The vector of any one of claims 1 to 6, wherein said
ii. a first nucleic acid sequence that hybridizes to the
vector further comprises a nucleic acid encoding a target 55
nucleic acid of SEQ ID NO: 1 under stringent condiprotein.
tions comprising hybridizing at 68° in 5xSSC/5xDen9. A recombinant cell line comprising any one of the vechardt's solution/1.0% SDS, and washing in 0.2xSSC/
tors of claims 1 to 6.
0.1% SDS at room temperature and a second nucleic
10. A method of enhancing target protein production of a
acid sequence that hybridizes to SEQ ID NO: 3 under
60
cell line producing a target protein comprising:
stringent conditions comprising hybridizing at 680 in
a. transforming cells of said cell line with a vankyrin
5xSSC/5xDenhardt's solution/1.0% SDS, and washexpression vector comprising a first polynucleotide
ing in 0.2xSSC/0.1% SDS at room temperature;
encoding one or more target proteins; said vankyrin
wherein the first and second nucleic acid sequences
expression vector further comprising a second polyeach encode a polypeptide capable of enhancing lon65
nucleotide selected from the group consisting of:
gevity and/or protein production of a cell line in which
it is expressed, compared to wild type cell counterpart
i. a nucleic acid encoding the polypeptide of SEQ ID
NO: 2 and the polypeptide of SEQ ID NO: 4;
of the cell line;
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iii. a nucleic acid comprising SEQ ID NO: 1 and SEQ ID
N0:3;
iv. a nucleic acid encoding the polypeptide of SEQ ID
N0:4;
v. a nucleic acid that hybridizes to the nucleic acid of
SEQ ID NO: 3 under stringent conditions comprising
hybridizing at 680 in 5xSSC/5xDenhardt's solution/
1.0% SDS, and washing in 0.2xSSC/0.1% SDS at
room temperature; wherein the nucleic acid encodes a
polypeptide capable of enhancing longevity and/or
protein production of a cell line in which it is
expressed, compared to wild type cell counterpart of
the cell line; and
vi. the nucleic acid of SEQ ID NO: 3.
12. A method of generating a recombinant target proteinproducing cell line capable of enhanced target protein production comprising:
a. constructing a vankyrin expression vector; said vankyrin
expression vector comprising a polynucleotide selected
from the group consisting of:
i. a nucleic acid encoding the polypeptide of SEQ ID
NO: 2 and the polypeptide of SEQ ID NO: 4;
ii. a first nucleic acid sequence that hybridizes to the
nucleic acid of SEQ ID NO: 1 under stringent conditions comprising hybridizing at 680 in 5xSSC/5x
Denhardt's solution/1.0% SDS, and washing in 0.2x
SSC/0.1% SDS at room temperature and a second
nucleic acid sequence that hybridizes to the nucleic
acid of SEQ ID NO: 3 under stringent conditions
comprising hybridizing at 68° in 5xSSC/5xDenhardt's solution/1.0% SDS, and washing in 0.2xSSC/
0.1% SDS at room temperature; wherein the first and
second nucleic acid sequences each encode a
polypeptide capable of enhancing longevity and/or
protein production of a cell line in which it is
expressed, compared to wild type cell counterpart of
the cell line;
iii. a nucleic acid comprising SEQ ID NO: 1 and SEQ ID
N0:3;
iv. a nucleic acid encoding the polypeptide of SEQ ID
N0:4;
v. a nucleic acid that hybridizes to the nucleic acid of
SEQ ID NO: 3 under stringent conditions comprising
hybridizing at 68° in 5xSSC/5xDenhardt's solution/
1.0% SDS, and washing in 0.2xSSC/0.1% SDS at
room temperature; wherein the nucleic acid encodes a
polypeptide capable of enhancing longevity and/or
protein production of a cell line in which it is
expressed, compared to wild type cell counterpart of
the cell line; and
vi. the nucleic acid of SEQ ID NO: 3; and
b. transforming cells of said cell line with the vankyrin
expression vector.
13. A method of enhancing longevity of a cell line producing a target protein comprising:
a. transforming cells of said cell line with a vankyrin
expression vector, said vankyrin expression vector comprising a polynucleotide selected from the group consisting of:
i. a nucleic acid encoding the polypeptide of SEQ ID
NO: 2 and the polypeptide of SEQ ID NO: 4;
ii. a first nucleic acid sequence that hybridizes to the
nucleic acid of SEQ ID NO: 1 under stringent conditions comprising hybridizing at 680 in 5xSSC/5x
Denhardt's solution/1.0% SDS, and washing in 0.2x
SSC/0.1% SDS at room temperature and a second
nucleic acid sequence that that hybridizes to the
nucleic acid of SEQ ID NO: 3 under stringent condi-

tions comprising hybridizing at 680 in 5xSSC/5x
Denhardt's solution/1.0% SDS, and washing in 0.2x
SSC/0.1% SDS at room temperature; wherein the first
and second nucleic acid sequences each encode a
polypeptide capable of enhancing longevity and/or
protein production of a cell line in which it is
expressed, compared to wild type cell counterpart of
the cell line;
iii. a nucleic acid sequence comprising SEQ ID NO: 1
and SEQ ID NO: 3;
iv. a nucleic acid encoding the polypeptide of SEQ ID
N0·4·
v. a n~cl~ic acid that hybridizes to the nucleic acid of
SEQ ID NO: 3 under stringent conditions comprising
hybridizing at 68° in 5xSSC/5xDenhardt's solution/
1.0% SDS, and washing in 0.2xSSC/0.1% SDS at
room temperature; wherein the nucleic acid encodes a
polypeptide capable of enhancing longevity and/or
protein production of a cell line in which it is
expressed, compared to wild type cell counterpart of
the cell line; and
vi. the nucleic acid of SEQ ID NO: 3; and
b. obtaining a transformed cell line having a longevity
greater than the same cell line lacking said vankyrin
expression vector.
14. The method of any one of claims 10-13 wherein said
cell line is an Spodoptora frugiperda 9 (Sf9) or an Spodoptera
littoralis 2 cell line.
15. The method of any one of claims 10-13 wherein said
vector is a baculovirus expression vector.
16. The method of any one of claims 10-13 wherein the
vector is stably transfected or transformed.
17. The method of any one of claims 10-13, wherein the
target protein is encoded by a polynucleotide that is heterologous to the cell line.
18. The method of any one of claims 10, 12 or 13 wherein
said target protein is an endogenous protein to the cell line.
19. The method of any one of claims 10-13 wherein the
vector is transiently transfected.
20. An isolated nucleic acid encoding the polypeptide is of
SEQ ID NO: 2 and the polypeptide of SEQ ID N0:4.
21. An isolated nucleic acid encoding a polypeptide having
the sequence of SEQ ID NO: 4.
22. An isolated nucleic acid comprising a first nucleotide
sequence that hybridizes to the full length complement of
SEQ ID NO: 1 under stringent conditions comprising hybridizing at 68° in 5xSSC/5xDenhardt's solution/1.0% SDS, and
washing in 0.2xSSC/0.1% SDS at room temperature and a
second nucleic acid sequence that hybridizes to the full length
complement of SEQ ID NO: 3 under stringent conditions
comprising hybridizing at 680 in 5xSSC/5xDenhardt's solution/1.0% SDS, and washing in 0.2xSSC/0.1% SDS at room
temperature; wherein the first and second nucleic acid
sequences each encodes a single polypeptide capable of
enhancing longevity of a cell line in which it is expressed,
compared to wild type cell counterpart of the cell line.
23. An isolated nucleic acid that hybridizes to the full
length complement of SEQ ID NO: 3 under stringent conditions comprising hybridizing at 68° in 5xSSC/5xDenhardt's
solution/1.0% SDS, and washing in 0.2xSSC/0.1% SDS at
room temperature; wherein the nucleic acid encodes a
polypeptide capable of enhancing longevity of a cell line in
which it is expressed, compared to wild type cell counterpart
of the cell line.
24. An isolated nucleic acid consisting of SEQ ID NO: 3.
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